New Zealand’s High Court has set aside regulations that barred new prescriptions of puberty blockers for gender dysphoria or gender incongruence, holding that the measure was adopted without the consultation required by the Medicines Act and unjustifiably discriminated against affected young people.
Justice Churchman’s final decision in Professional Association for Transgender Health Aotearoa Inc v Minister of Health concerned regulations that stopped clinicians from beginning puberty-blocker treatment for those conditions while preserving existing prescriptions and leaving use for other medical conditions untouched. Interim orders had prevented the prohibition from taking effect while the challenge was heard.
The court found that the consultation preceding the regulations did not address the substance of an indefinite prohibition and did not directly involve gender-diverse young people who would bear its effects. That was insufficient for the consultation duty in section 105 of the Medicines Act. The judgment also held that the measure drew a distinction on the ground of disability for the purposes of section 19 of the New Zealand Bill of Rights Act. A blanket and open-ended ban was not a proportionate way to pursue the government’s stated objective.
The ruling was not a wholesale acceptance of every argument advanced by the association. The judge rejected claims that the minister had improperly surrendered the decision to Cabinet or acted for an unauthorised purpose. The court did not determine the remaining Bill of Rights claims under sections 8, 9 and 10 because the consultation and discrimination findings were enough to dispose of the regulations.
The legal effect is final at High Court level: the regulations were declared unlawful and invalid and were set aside. Any appeal would require a separate step, and the judgment records no stay of the orders. The court also maintained strict suppression protections for the young people and witnesses whose circumstances informed the proceeding.
The decision leaves clinical prescribing to the legal framework that existed before the regulations, subject to ordinary professional and medicines controls. It does not itself direct that any patient receive treatment, and it does not resolve the wider medical debate. Its immediate significance lies in the limits it places on executive use of medicines regulations where a targeted prohibition is adopted without adequate participation by the people most directly affected.
Read the official High Court judgment.
